The pharmacodynamic and differential gene expression analysis of PPAR α/δ agonist GFT505 in CDAHFD-induced NASH model.
Peroxisome proliferator-activated receptor α/δ (PPAR α/δ), regulating glucolipid metabolism and immune inflammation, has been identified as an effective therapeutic target in non-alcoholic steatohepatitis (NASH). Dual PPAR α/δ agonist, such as GFT505 (also known as elafibranor), demonstrated potenti...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0243911 |
id |
doaj-001cd9c22611439d8f3c3e95d8b9971f |
---|---|
record_format |
Article |
spelling |
doaj-001cd9c22611439d8f3c3e95d8b9971f2021-03-04T13:00:40ZengPublic Library of Science (PLoS)PLoS ONE1932-62032020-01-011512e024391110.1371/journal.pone.0243911The pharmacodynamic and differential gene expression analysis of PPAR α/δ agonist GFT505 in CDAHFD-induced NASH model.Linfu LiuChuang LiuManyu ZhaoQianru ZhangYing LuPing LiuHua YangJinliang YangXiaoxin ChenYuqin YaoPeroxisome proliferator-activated receptor α/δ (PPAR α/δ), regulating glucolipid metabolism and immune inflammation, has been identified as an effective therapeutic target in non-alcoholic steatohepatitis (NASH). Dual PPAR α/δ agonist, such as GFT505 (also known as elafibranor), demonstrated potential therapeutic effect for NASH in clinical trials. To profile the regulatory network of PPAR α/δ agonist in NASH, the choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD) induced NASH model was used to test the pharmacodynamics and transcriptome regulation of GFT505 in this study. The results showed that GFT505 ameliorated hepatic steatosis, inflammation and fibrosis in CDAHFD mice model. RNA-sequencing yielded 3995 up-regulated and 3576 down-regulated genes with GFT505 treatment. And the most significant differentialy expressed genes involved in glucolipid metabolism (Pparα, Acox1, Cpt1b, Fabp4, Ehhadh, Fabp3), inflammation (Ccl6, Ccl9, Cxcl14) and fibrosis (Timp1, Lamc3, Timp2, Col3a1, Col1a2, Col1a1, Hapln4, Timp3, Pik3r5, Pdgfα, Pdgfβ, Tgfβ1, Tgfβ2) were confirmed by RT-qPCR. The down-regulated genes were enriched in cytokine-cytokine receptor interaction pathway and ECM-receptor interaction pathway, while the up-regulated genes were enriched in PPAR signaling pathway and fatty acid degradation pathway. This study provides clues and basis for further understanding on the mechanism of PPAR α/δ agonist on NASH.https://doi.org/10.1371/journal.pone.0243911 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Linfu Liu Chuang Liu Manyu Zhao Qianru Zhang Ying Lu Ping Liu Hua Yang Jinliang Yang Xiaoxin Chen Yuqin Yao |
spellingShingle |
Linfu Liu Chuang Liu Manyu Zhao Qianru Zhang Ying Lu Ping Liu Hua Yang Jinliang Yang Xiaoxin Chen Yuqin Yao The pharmacodynamic and differential gene expression analysis of PPAR α/δ agonist GFT505 in CDAHFD-induced NASH model. PLoS ONE |
author_facet |
Linfu Liu Chuang Liu Manyu Zhao Qianru Zhang Ying Lu Ping Liu Hua Yang Jinliang Yang Xiaoxin Chen Yuqin Yao |
author_sort |
Linfu Liu |
title |
The pharmacodynamic and differential gene expression analysis of PPAR α/δ agonist GFT505 in CDAHFD-induced NASH model. |
title_short |
The pharmacodynamic and differential gene expression analysis of PPAR α/δ agonist GFT505 in CDAHFD-induced NASH model. |
title_full |
The pharmacodynamic and differential gene expression analysis of PPAR α/δ agonist GFT505 in CDAHFD-induced NASH model. |
title_fullStr |
The pharmacodynamic and differential gene expression analysis of PPAR α/δ agonist GFT505 in CDAHFD-induced NASH model. |
title_full_unstemmed |
The pharmacodynamic and differential gene expression analysis of PPAR α/δ agonist GFT505 in CDAHFD-induced NASH model. |
title_sort |
pharmacodynamic and differential gene expression analysis of ppar α/δ agonist gft505 in cdahfd-induced nash model. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2020-01-01 |
description |
Peroxisome proliferator-activated receptor α/δ (PPAR α/δ), regulating glucolipid metabolism and immune inflammation, has been identified as an effective therapeutic target in non-alcoholic steatohepatitis (NASH). Dual PPAR α/δ agonist, such as GFT505 (also known as elafibranor), demonstrated potential therapeutic effect for NASH in clinical trials. To profile the regulatory network of PPAR α/δ agonist in NASH, the choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD) induced NASH model was used to test the pharmacodynamics and transcriptome regulation of GFT505 in this study. The results showed that GFT505 ameliorated hepatic steatosis, inflammation and fibrosis in CDAHFD mice model. RNA-sequencing yielded 3995 up-regulated and 3576 down-regulated genes with GFT505 treatment. And the most significant differentialy expressed genes involved in glucolipid metabolism (Pparα, Acox1, Cpt1b, Fabp4, Ehhadh, Fabp3), inflammation (Ccl6, Ccl9, Cxcl14) and fibrosis (Timp1, Lamc3, Timp2, Col3a1, Col1a2, Col1a1, Hapln4, Timp3, Pik3r5, Pdgfα, Pdgfβ, Tgfβ1, Tgfβ2) were confirmed by RT-qPCR. The down-regulated genes were enriched in cytokine-cytokine receptor interaction pathway and ECM-receptor interaction pathway, while the up-regulated genes were enriched in PPAR signaling pathway and fatty acid degradation pathway. This study provides clues and basis for further understanding on the mechanism of PPAR α/δ agonist on NASH. |
url |
https://doi.org/10.1371/journal.pone.0243911 |
work_keys_str_mv |
AT linfuliu thepharmacodynamicanddifferentialgeneexpressionanalysisofpparadagonistgft505incdahfdinducednashmodel AT chuangliu thepharmacodynamicanddifferentialgeneexpressionanalysisofpparadagonistgft505incdahfdinducednashmodel AT manyuzhao thepharmacodynamicanddifferentialgeneexpressionanalysisofpparadagonistgft505incdahfdinducednashmodel AT qianruzhang thepharmacodynamicanddifferentialgeneexpressionanalysisofpparadagonistgft505incdahfdinducednashmodel AT yinglu thepharmacodynamicanddifferentialgeneexpressionanalysisofpparadagonistgft505incdahfdinducednashmodel AT pingliu thepharmacodynamicanddifferentialgeneexpressionanalysisofpparadagonistgft505incdahfdinducednashmodel AT huayang thepharmacodynamicanddifferentialgeneexpressionanalysisofpparadagonistgft505incdahfdinducednashmodel AT jinliangyang thepharmacodynamicanddifferentialgeneexpressionanalysisofpparadagonistgft505incdahfdinducednashmodel AT xiaoxinchen thepharmacodynamicanddifferentialgeneexpressionanalysisofpparadagonistgft505incdahfdinducednashmodel AT yuqinyao thepharmacodynamicanddifferentialgeneexpressionanalysisofpparadagonistgft505incdahfdinducednashmodel AT linfuliu pharmacodynamicanddifferentialgeneexpressionanalysisofpparadagonistgft505incdahfdinducednashmodel AT chuangliu pharmacodynamicanddifferentialgeneexpressionanalysisofpparadagonistgft505incdahfdinducednashmodel AT manyuzhao pharmacodynamicanddifferentialgeneexpressionanalysisofpparadagonistgft505incdahfdinducednashmodel AT qianruzhang pharmacodynamicanddifferentialgeneexpressionanalysisofpparadagonistgft505incdahfdinducednashmodel AT yinglu pharmacodynamicanddifferentialgeneexpressionanalysisofpparadagonistgft505incdahfdinducednashmodel AT pingliu pharmacodynamicanddifferentialgeneexpressionanalysisofpparadagonistgft505incdahfdinducednashmodel AT huayang pharmacodynamicanddifferentialgeneexpressionanalysisofpparadagonistgft505incdahfdinducednashmodel AT jinliangyang pharmacodynamicanddifferentialgeneexpressionanalysisofpparadagonistgft505incdahfdinducednashmodel AT xiaoxinchen pharmacodynamicanddifferentialgeneexpressionanalysisofpparadagonistgft505incdahfdinducednashmodel AT yuqinyao pharmacodynamicanddifferentialgeneexpressionanalysisofpparadagonistgft505incdahfdinducednashmodel |
_version_ |
1714800797185736704 |